Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment

Overview of attention for article published in Breast Cancer Research and Treatment, January 2009

Altmetric Badge

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 51 Dimensions

Readers on

mendeley: 86 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer : Appraisal consultation 1 committee papers

Cited by National Institute for Health and Care Excellence on 08 Jun 2018

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer: Committee papers

Cited by National Institute for Health and Care Excellence on 09 Nov 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.